299 related articles for article (PubMed ID: 28984642)
1. Viral infections in solid organ transplant recipients: novel updates and a review of the classics.
Haidar G; Singh N
Curr Opin Infect Dis; 2017 Dec; 30(6):579-588. PubMed ID: 28984642
[TBL] [Abstract][Full Text] [Related]
2. Prophylaxis against herpesvirus infections in transplant recipients.
Ljungman P
Drugs; 2001; 61(2):187-96. PubMed ID: 11270937
[TBL] [Abstract][Full Text] [Related]
3. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.
Torres-Madriz G; Boucher HW
Clin Infect Dis; 2008 Sep; 47(5):702-11. PubMed ID: 18652557
[TBL] [Abstract][Full Text] [Related]
4. Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study.
Papanicolaou GA; Silveira FP; Langston AA; Pereira MR; Avery RK; Uknis M; Wijatyk A; Wu J; Boeckh M; Marty FM; Villano S
Clin Infect Dis; 2019 Apr; 68(8):1255-1264. PubMed ID: 30329038
[TBL] [Abstract][Full Text] [Related]
5. Prevention and Treatment of Cytomegalovirus Infections in Solid Organ Transplant Recipients.
Koval CE
Infect Dis Clin North Am; 2018 Sep; 32(3):581-597. PubMed ID: 30146024
[TBL] [Abstract][Full Text] [Related]
6. The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients.
Roman A; Manito N; Campistol JM; Cuervas-Mons V; Almenar L; Arias M; Casafont F; del Castillo D; Crespo-Leiro MG; Delgado JF; Herrero JI; Jara P; Morales JM; Navarro M; Oppenheimer F; Prieto M; Pulpón LA; Rimola A; Serón D; Ussetti P;
Transplant Rev (Orlando); 2014 Apr; 28(2):84-91. PubMed ID: 24602805
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies.
Singh N
J Clin Virol; 2006 Apr; 35(4):474-7. PubMed ID: 16406798
[TBL] [Abstract][Full Text] [Related]
8. Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections.
Razonable RR; Paya CV
Herpes; 2003 Dec; 10(3):60-5. PubMed ID: 14759337
[TBL] [Abstract][Full Text] [Related]
9. Viral load, CMV-specific T-cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy.
Martín-Gandul C; Pérez-Romero P; Blanco-Lobo P; Benmarzouk-Hidalgo OJ; Sánchez M; Gentil MA; Bernal C; Sobrino JM; Rodríguez-Hernández MJ; Cordero E;
Transpl Int; 2014 Oct; 27(10):1060-8. PubMed ID: 24964364
[TBL] [Abstract][Full Text] [Related]
10. Updates in Cytomegalovirus Prevention and Treatment in Solid Organ Transplantation.
Doss KM; Heldman MR; Limaye AP
Infect Dis Clin North Am; 2023 Nov; ():. PubMed ID: 37989636
[TBL] [Abstract][Full Text] [Related]
11. A risk-stratified approach to cytomegalovirus prevention in pediatric solid organ transplant recipients.
Suresh S; Lee BE; Robinson JL; Akinwumi MS; Preiksaitis JK
Pediatr Transplant; 2016 Nov; 20(7):970-980. PubMed ID: 27565955
[TBL] [Abstract][Full Text] [Related]
12. Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients.
Le Page AK; Jager MM; Iwasenko JM; Scott GM; Alain S; Rawlinson WD
Clin Infect Dis; 2013 Apr; 56(7):1018-29. PubMed ID: 23243176
[TBL] [Abstract][Full Text] [Related]
13. Prevention of viral infections in solid organ transplant recipients in the era of COVID-19: a narrative review.
Filippidis P; Vionnet J; Manuel O; Mombelli M
Expert Rev Anti Infect Ther; 2022 May; 20(5):663-680. PubMed ID: 34854329
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of cytomegalovirus viral load in solid organ transplant recipients.
Dioverti MV; Razonable RR
Curr Opin Infect Dis; 2015 Aug; 28(4):317-22. PubMed ID: 26098497
[TBL] [Abstract][Full Text] [Related]
15. [Cytomegalovirus infection after solid-organ transplantation, its risk factors, direct and indirect effects and prevention strategies].
Varga M; Remport A; Czebe K; Péter A; Toronyi E; Sárváry E; Fehérvári I; Sulyok B; Járay J
Orv Hetil; 2008 Mar; 149(12):551-8. PubMed ID: 18343771
[TBL] [Abstract][Full Text] [Related]
16. Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients.
Pascual J; Royuela A; Fernández AM; Herrero I; Delgado JF; Solé A; Guirado L; Serrano T; de la Torre-Cisneros J; Moreno A; Cordero E; Gallego R; Lumbreras C; Aguado JM;
Transpl Infect Dis; 2016 Dec; 18(6):819-831. PubMed ID: 27600985
[TBL] [Abstract][Full Text] [Related]
17. Infections in solid organ transplant HIV-infected patients.
Miro JM; Agüero F; Duclos-Vallée JC; Mueller NJ; Grossi P; Moreno A;
Clin Microbiol Infect; 2014 Sep; 20 Suppl 7():119-30. PubMed ID: 25040016
[TBL] [Abstract][Full Text] [Related]
18. Approach to drug-resistant cytomegalovirus in transplant recipients.
Chou S
Curr Opin Infect Dis; 2015 Aug; 28(4):293-9. PubMed ID: 26098499
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report.
Iwami D; Ogawa Y; Fujita H; Morita K; Sasaki H; Oishi Y; Higuchi H; Hatanaka K; Shinohara N
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():63-6. PubMed ID: 26970406
[TBL] [Abstract][Full Text] [Related]
20. Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy.
Singh N
Rev Med Virol; 2006; 16(5):281-7. PubMed ID: 16878336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
